TNFRSF8 and Hodgkins lymphoma: Encouraging data comes from a Phase I clinical study in which an anti-CD16/anti-CD30 bispecific NK-cell engager combined with pembrolizumab has shown an ORR of 83% and a CR rate of 46% in patients with relapsed or refractory Hodgkin Lymphoma (HL) (87).